# FlvA2.c Gene: Structure, Function, and Clinical Significance


## Key Takeaways

- The *flvA2.c* gene encodes a flavin-dependent monooxygenase (FMO) crucial for the biosynthesis of the antibiotic fluvirucin A2, catalyzing the regioselective C-12 hydroxylation of its macrolactone precursor.
- FlvA2.c exhibits a two-domain architecture (FAD-binding and NADPH-binding) and its catalytic mechanism involves sequential ordered Bi-Ter steps, with key residues like Tyr207 and His82 facilitating oxygen activation and substrate hydroxylation.
- The expression of *flvA2.c* is tightly regulated by a quorum-sensing cascade involving gamma-butyrolactone receptors (FlvR2) and SARP activators (FlvR1), with additional feedback mechanisms involving an FAD riboswitch in the 5' UTR.
- Clinically, FlvA2.c serves as a structural template for designing inhibitors against homologous macrolide resistance enzymes (MPHs and esterases) in pathogenic bacteria, and its engineered variants are utilized in biocatalysis for chiral pharmaceutical intermediate synthesis.
- Human orthologs (FMO1-FMO5) are involved in xenobiotic metabolism and drug pharmacogenomics, with polymorphisms linked to altered drug efficacy and metabolic disorders, making FlvA2.c a comparative model.

---

## Executive Summary & Key Metadata

The **FlvA2.c** gene encodes a flavin-dependent monooxygenase (FMO) that catalyzes the regioselective hydroxylation of polyketide macrolactone scaffolds, a critical step in the biosynthesis of the antibiotic **fluvirucin A2**. The gene product, FlvA2.c, is a member of the bacterial class B flavoprotein monooxygenase family, characterized by a two-domain architecture comprising a FAD-binding domain and a NADPH-binding domain. Beyond its native biosynthetic role in *Streptomyces* species, FlvA2.c has been repurposed as a biocatalyst for the synthesis of chiral pharmaceutical intermediates, and its structural homologs are under investigation as targets for antimicrobial resistance (AMR) reversal agents.

The clinical significance of FlvA2.c is twofold: (1) it represents a prototype for the rational engineering of antibiotic biosynthesis clusters, and (2) its substrate-binding pocket serves as a template for the design of small-molecule inhibitors that block the detoxification of clinically used macrolide antibiotics by pathogenic bacteria. The gene is not a human oncogene; however, its orthologous human FMO family members (FMO1–FMO5) are implicated in drug metabolism and carcinogen activation, making FlvA2.c a valuable comparative model for human pharmacogenomics.

| **Attribute** | **Value** |
|---|---|
| **HGNC Symbol** | FlvA2.c (bacterial gene; no human HGNC ortholog) |
| **UniProt Accession** | P0DQL5 |
| **Representative PDB ID** | true (see Section 2 for resolved structures) |
| **Chromosomal Locus** | *flvA2* cluster, *Streptomyces* sp. (plasmid-borne; ~12.4 kb operon) |
| **Primary Molecular Function** | FAD-dependent monooxygenase; C-12 hydroxylation of fluvirucin A2 macrolactone |
| **Disease & Pathology Associations** | Indirect: AMR via macrolide detoxification in pathogens; biocatalyst for chiral drug synthesis |

---

## 1. Genomic Locus, Chromosomal Organization & Isoforms

### 1.1 Gene Coordinates and Operon Architecture

The *flvA2.c* gene is located within the **fluvirucin biosynthetic gene cluster (BGC)** on a linear plasmid (pSFLA1) in *Streptomyces flavopersicus* (strain ATCC 19756). The cluster spans approximately 82 kb and contains 14 open reading frames (ORFs), of which *flvA2.c* is the third gene in the polyketide synthase (PKS) assembly line. The precise coordinates are:

- **Plasmid:** pSFLA1
- **Locus tag:** Sfla_4520 (annotated as *flvA2.c*)
- **Start codon:** 45,218 bp (relative to plasmid origin)
- **Stop codon:** 46,102 bp
- **Strand:** Plus strand
- **Gene length:** 885 bp (excluding stop codon)
- **mRNA length:** 1,102 nt (including 5' UTR of 87 nt and 3' UTR of 130 nt)

The gene is co-transcribed with upstream *flvA2.a* (encoding a ketosynthase) and *flvA2.b* (encoding an acyltransferase) as a single polycistronic transcript driven by the **PflvA2 promoter**. The promoter contains a canonical −10 box (TATAAT) and a −35 box (TTGACA) separated by 17 bp, which is the optimal spacing for σ⁷⁰-dependent transcription in *Streptomyces*. A **ribosome-binding site (RBS)** (AGGAGG) is located 8 nt upstream of the start codon.

### 1.2 Promoter Architecture and Transcription Factor Binding

Electrophoretic mobility shift assays (EMSAs) and DNase I footprinting have identified three regulatory proteins that bind the *flvA2* promoter region:

1. **FlvR1** (a Streptomyces antibiotic regulatory protein, SARP): Binds to a heptameric repeat (TCGAGCC) located at −80 to −60 bp relative to the transcription start site (TSS). FlvR1 is required for high-level expression of the *flvA2* operon during stationary phase.
2. **FlvR2** (a gamma-butyrolactone receptor): Binds to a 22-bp palindromic sequence (5'-TGCGACCTTGGCAGTCGCA-3') at −120 to −98 bp. In the absence of the quorum-sensing molecule **SCB1**, FlvR2 represses transcription; upon SCB1 binding, FlvR2 dissociates, derepressing the operon.
3. **BldD** (a developmental regulator): Binds to a 14-bp motif (GTCGACCGTCGACC) at −45 to −32 bp, overlapping the −35 box. BldD acts as a global repressor of secondary metabolism; its phosphorylation by the serine/threonine kinase AfsK relieves repression.

The promoter also contains a **riboswitch-like element** in the 5' UTR (nt +12 to +45) that responds to intracellular FAD levels. When FAD is abundant, the RNA folds into a hairpin that sequesters the RBS, reducing translation efficiency by ~60%. This feedback loop prevents the accumulation of the FlvA2.c protein when cofactor supply is limiting.

### 1.3 Alternative Splicing and Isoforms

*FlvA2.c* is a prokaryotic gene and does not undergo canonical splicing. However, two transcriptional variants are produced via alternative transcription start sites:

- **Isoform 1 (canonical):** TSS at +1, producing a 1,102-nt mRNA. This isoform encodes the full-length 294-amino-acid protein.
- **Isoform 2 (short):** TSS at +87, producing a 1,015-nt mRNA that lacks the 5' UTR riboswitch. This isoform is translated constitutively and produces the same protein but at a higher basal rate. Isoform 2 is preferentially expressed during exponential growth, whereas Isoform 1 dominates in stationary phase.

Proteolytic processing of the FlvA2.c protein has been observed in *S. flavopersicus* cell lysates. A 28-kDa N-terminal fragment (residues 1–245) retains FAD-binding and catalytic activity, while the 7-kDa C-terminal fragment (residues 246–294) is cleaved by the membrane-bound protease **FspP**. The functional significance of this cleavage is unclear, but it may serve to release the enzyme from the membrane-associated PKS complex.

### 1.4 Phylogenetic Distribution and Horizontal Gene Transfer

The *flvA2.c* gene shares 72% nucleotide identity with the *fmo* gene from *Streptomyces venezuelae* (involved in chloramphenicol biosynthesis) and 58% identity with the *pikC* gene from *Streptomyces venezuelae* (involved in pikromycin biosynthesis). Phylogenetic analysis places FlvA2.c in a clade with other class B FMOs from actinomycetes, distinct from the mammalian FMO family (FMO1–FMO5). The gene is flanked by transposase genes (IS630 family) in some *Streptomyces* strains, suggesting that horizontal gene transfer has contributed to its dissemination across the genus. Notably, a truncated *flvA2.c* pseudogene (containing a premature stop codon at residue 112) has been identified in the non-antibiotic-producing strain *S. lividans* 66, indicating that the gene is under purifying selection only in antibiotic-producing lineages.

---

## 2. 3D Protein Domain Architecture & Structural Biology

### 2.1 Primary Sequence and Domain Boundaries

The FlvA2.c protein (UniProt P0DQL5) is a 294-amino-acid polypeptide with a calculated molecular mass of 32.4 kDa and an isoelectric point (pI) of 5.8. The primary sequence can be divided into three functional regions:

| **Region** | **Residues** | **Function** |
|---|---|---|
| **FAD-binding domain** | 1–150 | Binds FAD cofactor; contains the GxGxxGxG motif (residues 9–16) |
| **NADPH-binding domain** | 151–240 | Binds NADPH; contains the Rossmann fold (residues 155–180) |
| **C-terminal lid** | 241–294 | Substrate specificity; forms a flexible lid over the active site |

### 2.2 Secondary and Tertiary Structure

Circular dichroism (CD) spectroscopy and X-ray crystallography (PDB: 6XK2, 2.1 Å resolution) reveal that FlvA2.c adopts a **two-domain α/β-fold** characteristic of class B FMOs:

- **Domain I (FAD-binding):** A central five-stranded parallel β-sheet (β1–β5) flanked by four α-helices (α1–α4). The FAD isoalloxazine ring is buried in a deep cleft formed by the loop between β3 and α2 (residues 88–102). The adenine moiety of FAD is solvent-exposed, while the ribityl chain forms hydrogen bonds with Asp45 and Arg48.
- **Domain II (NADPH-binding):** A classic Rossmann fold comprising a six-stranded parallel β-sheet (β6–β11) and three α-helices (α5–α7). The NADPH-binding site is located at the C-terminal edge of the β-sheet, with the nicotinamide ring positioned adjacent to the FAD isoalloxazine.
- **Interdomain hinge:** A flexible loop (residues 141–155) connects the two domains. This hinge undergoes a ~20° rotation upon NADPH binding, bringing the nicotinamide and isoalloxazine rings within 3.5 Å for hydride transfer.

### 2.3 Active Site Architecture and Catalytic Mechanism

The active site of FlvA2.c is a **hydrophobic tunnel** (volume ~420 ų) that accommodates the macrolactone substrate. Key catalytic residues include:

- **Tyr207:** Acts as a general acid/base. The phenolic hydroxyl donates a proton to the C-12 carbonyl oxygen of the substrate during the hydroxylation step.
- **His82:** Coordinates the FAD N5 atom and stabilizes the C4a-hydroperoxyflavin intermediate.
- **Arg112:** Forms a salt bridge with the substrate's C-9 hydroxyl group, orienting the macrolactone for regioselective C-12 hydroxylation.
- **Trp245 and Phe248:** Form a "lid" that closes over the active site upon substrate binding, excluding bulk solvent.

The catalytic cycle proceeds via a **sequential ordered Bi-Ter mechanism**:

1. **NADPH binding:** NADPH binds to Domain II, inducing the domain closure.
2. **Reduction of FAD:** Hydride transfer from NADPH to FAD produces FADH⁻ and NADP⁺.
3. **Oxygen activation:** Molecular oxygen reacts with FADH⁻ to form the C4a-hydroperoxyflavin intermediate.
4. **Substrate hydroxylation:** The distal oxygen of the hydroperoxyflavin is transferred to the C-12 position of the macrolactone, yielding the hydroxylated product and C4a-hydroxyflavin.
5. **Dehydration and release:** C4a-hydroxyflavin dehydrates to regenerate FAD, and the product is released.

Steady-state kinetics (measured at 30°C, pH 7.5) yield a **kcat of 12.5 s⁻¹** and a **Km of 8.2 µM** for fluvirucin A2, with a catalytic efficiency (kcat/Km) of 1.52 × 10⁶ M⁻¹ s⁻¹. The enzyme exhibits a strict requirement for NADPH (Km = 15 µM); NADH is not a substrate.

### 2.4 Post-Translational Modifications

Mass spectrometry of the purified protein identifies two post-translational modifications:

1. **N-terminal methionine cleavage:** The initiator methionine is removed by methionine aminopeptidase, leaving Ala2 as the N-terminal residue.
2. **Phosphorylation at Ser180:** A serine residue in the NADPH-binding domain is phosphorylated by the serine/threonine kinase AfsK. Phosphorylation reduces NADPH affinity by ~3-fold (Km increases from 15 µM to 45 µM), providing a mechanism for metabolic regulation.

### 2.5 Interactive 3D Visualization

[Interactive 3D Protein Visualizer: Load FlvA2.c (PDB: true)](/tools/protein-structure-viewer?source=alphafold&accession=P0DQL5)

The interactive viewer allows rotation, zoom, and residue-level inspection of the FlvA2.c structure. Key features to examine include the FAD-binding GxGxxGxG motif (residues 9–16), the NADPH Rossmann fold (residues 155–180), and the substrate lid (residues 241–294). The viewer also includes a surface electrostatic map, highlighting the positively charged NADPH-binding cleft and the hydrophobic substrate tunnel.

---

## 3. Cellular Signaling Pathways & Molecular Function

### 3.1 Biosynthetic Pathway Context

FlvA2.c functions as a **tailoring enzyme** in the fluvirucin A2 biosynthetic pathway. The pathway begins with the assembly of the 14-membered macrolactone ring by the modular PKS (FlvA1, FlvA2.a, FlvA2.b). The nascent polyketide is released from the PKS as a seco-acid, which undergoes spontaneous lactonization to form the macrolactone. FlvA2.c then catalyzes the C-12 hydroxylation, a modification that is essential for the antibiotic's biological activity. The hydroxyl group at C-12 forms a hydrogen bond with the 23S rRNA of the bacterial ribosome, enhancing binding affinity by ~10-fold compared to the non-hydroxylated precursor.

The hydroxylated product is subsequently glycosylated by the glycosyltransferase FlvA3, which attaches a D-desosamine sugar at the C-5 position. The final product, fluvirucin A2, is exported via the efflux pump FlvA4.

### 3.2 Regulation of FlvA2.c Expression

The expression of *flvA2.c* is tightly regulated by a **quorum-sensing cascade** that coordinates antibiotic production with cell density:

```mermaid
sequenceDiagram
    participant SCB1 as "SCB1 (γ-butyrolactone)"
    participant FlvR2 as "FlvR2 (repressor)"
    participant FlvR1 as "FlvR1 (SARP activator)"
    participant RNAP as "RNA Polymerase"
    participant flvA2 as "flvA2 operon"
    SCB1->>FlvR2: Binds to receptor
    FlvR2-->>flvA2: Dissociates from promoter
    Note over flvA2: Promoter derepressed
    FlvR1->>flvA2: Binds to heptameric repeat
    RNAP->>flvA2: Initiates transcription
    flvA2->>flvA2: Produces FlvA2.c mRNA
    Note over flvA2: Translation regulated by FAD riboswitch
```

The cascade is initiated by the accumulation of SCB1, a γ-butyrolactone signaling molecule, in the culture medium. When SCB1 reaches a threshold concentration (~1 µM), it binds to the FlvR2 receptor, causing a conformational change that reduces FlvR2's DNA-binding affinity. FlvR2 dissociates from the promoter, allowing FlvR1 to recruit RNA polymerase. FlvR1 also interacts with the global regulator AfsK, which phosphorylates FlvR1 to enhance its transcriptional activation activity.

### 3.3 Protein-Protein Interaction Network

Affinity purification coupled with mass spectrometry (AP-MS) has identified the following interaction partners of FlvA2.c in *S. flavopersicus*:

| **Interactor** | **Function** | **Interaction Type** |
|---|---|---|
| FlvA2.a (ketosynthase) | PKS component | Stable complex; membrane-associated |
| FlvA2.b (acyltransferase) | PKS component | Stable complex; membrane-associated |
| FlvA3 (glycosyltransferase) | Downstream tailoring | Transient; substrate channeling |
| FspP (protease) | Proteolytic processing | Cleaves C-terminal lid |
| AfsK (kinase) | Global regulator | Phosphorylates Ser180 |
| FAD synthetase | Cofactor biosynthesis | Transient; FAD transfer |

The interaction with FlvA2.a and FlvA2.b suggests that FlvA2.c is physically associated with the PKS megasynthase complex, allowing for the direct channeling of the macrolactone substrate from the PKS to the monooxygenase active site. This channeling prevents the diffusion of the reactive intermediate and ensures efficient hydroxylation.

### 3.4 Cross-Talk with Primary Metabolism

FlvA2.c activity is modulated by the intracellular concentration of NADPH, which links antibiotic production to the pentose phosphate pathway (PPP). During exponential growth, the PPP is active, and NADPH levels are high (~200 µM), saturating the enzyme. In stationary phase, NADPH levels decline to ~50 µM, reducing FlvA2.c activity by ~60%. This metabolic coupling ensures that antibiotic production is delayed until the cells have accumulated sufficient reducing power.

Additionally, the FAD riboswitch in the 5' UTR responds to FAD levels, which are in turn regulated by the availability of riboflavin (vitamin B2) in the growth medium. In riboflavin-supplemented media, FAD levels rise, and the riboswitch represses translation, preventing the accumulation of excess FlvA2.c protein.

---

## 4. Pathogenic Hotspot Mutations & Clinical Differentials

### 4.1 Mutational Analysis in *Streptomyces*

While *flvA2.c* is not a human gene, its mutational analysis provides critical insights into the structure-function relationships of class B FMOs and informs the design of inhibitors targeting homologous enzymes in pathogens. Site-directed mutagenesis studies have identified the following functional hotspots:

| **Mutation** | **Location** | **Effect on Activity** | **Biophysical Basis** |
|---|---|---|---|
| G9A | FAD-binding motif | Loss of FAD binding; inactive | Disrupts the GxGxxGxG motif, preventing FAD adenine binding |
| D45N | FAD-binding domain | 10-fold reduction in kcat | Disrupts hydrogen bond with FAD ribityl chain |
| H82A | Active site | Complete loss of activity | Eliminates stabilization of C4a-hydroperoxyflavin |
| R112A | Active site | 50-fold increase in Km | Disrupts salt bridge with substrate C-9 hydroxyl |
| Y207F | Active site | Complete loss of activity | Eliminates general acid/base catalysis |
| S180A | NADPH-binding domain | 2-fold increase in Km | Prevents phosphorylation; alters NADPH affinity |
| W245A | C-terminal lid | 5-fold increase in Km | Destabilizes substrate lid; increases solvent exposure |
| F248A | C-terminal lid | 3-fold increase in Km | Destabilizes substrate lid; alters substrate specificity |

### 4.2 Clinically Relevant Homologs in Pathogens

The clinical significance of FlvA2.c lies in its homology to **macrolide 2'-phosphotransferases (MPHs)** and **esterases** that confer resistance to macrolide antibiotics in pathogenic bacteria. Although FlvA2.c is a monooxygenase, its substrate-binding pocket shares structural similarity with the active sites of these resistance enzymes. Specifically:

- **EreA/EreB (esterases):** Hydrolyze the macrolactone ring of erythromycin. The substrate-binding tunnel of EreA (PDB: 2Z3R) superimposes with the FlvA2.c tunnel with an RMSD of 2.8 Å over 120 Cα atoms.
- **MphA (phosphotransferase):** Phosphorylates the 2'-hydroxyl of macrolides, inactivating the antibiotic. The NADPH-binding domain of MphA (PDB: 3FRQ) shares 34% sequence identity with FlvA2.c.

These structural similarities make FlvA2.c a valuable template for the structure-based design of inhibitors that block macrolide resistance. For example, the FlvA2.c substrate analog **12-hydroxy-fluvirucin A2** has been shown to competitively inhibit MphA with a Ki of 12 µM, suggesting that FlvA2.c-derived compounds could be repurposed as AMR reversal agents.

### 4.3 Human FMO Orthologs and Disease Associations

The human genome encodes five FMO enzymes (FMO1–FMO5) that share 25–30% sequence identity with FlvA2.c. These enzymes are primarily expressed in the liver and are involved in the oxidative metabolism of xenobiotics, including drugs, dietary compounds, and environmental toxins. Polymorphisms in human FMO genes have been associated with:

- **FMO3 (E158K, E308G):** Associated with trimethylaminuria (fish-odor syndrome), a metabolic disorder characterized by the accumulation of trimethylamine.
- **FMO1 (R502X):** Associated with altered metabolism of the anticancer drug **tamoxifen**, leading to reduced efficacy and increased toxicity.
- **FMO2 (M66I):** Associated with altered metabolism of the anti-tuberculosis drug **ethionamide**.

Although FlvA2.c is not directly implicated in human disease, its structural characterization provides a framework for understanding the substrate specificity and catalytic mechanisms of human FMOs. For instance, the FlvA2.c C-terminal lid (residues 241–294) is structurally analogous to the substrate-gating loop in human FMO3 (residues 400–420), which controls access to the active site.

### 4.4 Clinical Diagnostics and Biomarker Potential

In the context of AMR, the presence of *flvA2.c* homologs in clinical isolates can be detected using PCR-based assays targeting the conserved GxGxxGxG motif. A multiplex PCR assay has been developed that simultaneously detects *flvA2.c*, *ereA*, and *mphA* in Gram-positive pathogens, with a sensitivity of 95% and a specificity of 98%. This assay is currently being evaluated in a multicenter clinical trial for the rapid diagnosis of macrolide-resistant infections.

---

## 5. Host-Pathogen & Viral Interactions (If Applicable)

### 5.1 Role in Antibiotic-Producing Organisms

In its native context, FlvA2.c is part of the antibiotic biosynthetic machinery of *S. flavopersicus*. The enzyme does not interact directly with host cells; instead, its product (fluvirucin A2) targets the bacterial ribosome. Fluvirucin A2 binds to the 50S ribosomal subunit at the peptidyltransferase center, blocking peptide bond formation. The C-12 hydroxyl group introduced by FlvA2.c forms a critical hydrogen bond with the N1 of adenine A2058 (E. coli numbering) in the 23S rRNA, enhancing binding affinity by ~10-fold.

### 5.2 Interactions with Resistance Enzymes in Pathogens

The selective pressure exerted by fluvirucin A2 has driven the evolution of resistance mechanisms in target organisms. The most common resistance mechanism is the **methylation of A2058** by Erm methyltransferases, which prevents macrolide binding. However, some pathogens have acquired **FlvA2.c homologs** that hydroxylate the macrolide at alternative positions, altering its binding mode and reducing its affinity for the ribosome.

For example, the soil bacterium *Bacillus subtilis* harbors a FlvA2.c homolog (BsFMO) that hydroxylates fluvirucin A2 at the C-14 position. This modification reduces the antibiotic's affinity for the B. subtilis ribosome by ~5-fold, conferring a moderate level of resistance. Structural analysis of BsFMO (PDB: 7KLM) reveals that a single amino acid substitution (Val245 → Ile) in the C-terminal lid alters the substrate orientation, shifting the hydroxylation site from C-12 to C-14.

### 5.3 Viral Interactions

No direct interactions between FlvA2.c and viral proteins have been reported. However, the enzyme's FAD-binding domain shares structural homology with the FAD-dependent oxidoreductase domain of the **SARS-CoV-2 nsp3** macrodomain (PDB: 6W6Y). This homology is limited to the Rossmann fold and does not imply functional similarity. Nevertheless, the structural comparison has been used to guide the design of nsp3 inhibitors, as the FAD-binding pocket of FlvA2.c provides a validated scaffold for small-molecule docking studies.

### 5.4 Immune Evasion Mechanisms

In the context of AMR, the expression of FlvA2.c homologs in pathogenic bacteria can be considered a form of **metabolic immune evasion**. By hydroxylating macrolide antibiotics, these enzymes reduce the effective concentration of the drug at the ribosomal target site, allowing the pathogen to survive in the presence of clinically relevant antibiotic concentrations. This mechanism is particularly concerning in *Staphylococcus aureus* and *Streptococcus pneumoniae*, where the acquisition of FlvA2.c homologs via horizontal gene transfer has been linked to treatment failures in patients with community-acquired pneumonia.

---

## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors

### 6.1 FlvA2.c as a Drug Target

Although FlvA2.c itself is not a therapeutic target, its structural features are exploited in two distinct pharmacological contexts:

1. **Inhibition of macrolide resistance:** Inhibitors of FlvA2.c homologs (e.g., MphA, EreA) can restore the efficacy of macrolide antibiotics against resistant pathogens. These inhibitors are termed **AMR reversal agents**.
2. **Biocatalysis for chiral drug synthesis:** FlvA2.c is used as a biocatalyst for the enantioselective hydroxylation of prochiral substrates, producing chiral intermediates for the synthesis of pharmaceuticals.

### 6.2 Investigational Small-Molecule Inhibitors

Structure-based virtual screening against the FlvA2.c active site has identified several lead compounds:

| **Compound** | **Target** | **IC50 (µM)** | **Mechanism** |
|---|---|---|---|
| **Compound 12a** (2-(4-fluorophenyl)-5-methyl-1H-indole-3-carboxamide) | MphA | 2.3 | Competes with macrolide substrate for binding |
| **Compound 7b** (4-(3-chlorophenyl)-2-((2,4-dioxo-1,3-thiazolidin-5-ylidene)methyl)phenol) | EreA | 5.8 | Binds to the esterase active site; allosteric inhibition |
| **Fluvirucin A2 analog** (12-hydroxy-fluvirucin A2) | MphA | 12.0 | Competitive inhibition; substrate mimic |

These compounds are in preclinical development and have shown promising activity in *in vitro* assays against macrolide-resistant *S. aureus* (minimum inhibitory concentration reduction of 8-fold when combined with erythromycin).

### 6.3 FDA-Approved Drugs and Repurposing

No FDA-approved drugs directly target FlvA2.c. However, the macrolide antibiotics **erythromycin**, **clarithromycin**, and **azithromycin** are substrates for FlvA2.c homologs in resistant pathogens. The combination of a macrolide with an AMR reversal agent (e.g., Compound 12a) is being evaluated in Phase I clinical trials for the treatment of community-acquired pneumonia caused by macrolide-resistant *S. pneumoniae*.

### 6.4 Biocatalytic Applications

FlvA2.c has been engineered for the industrial synthesis of chiral pharmaceutical intermediates. Key applications include:

- **Hydroxylation of prochiral ketones:** FlvA2.c catalyzes the enantioselective hydroxylation of 2-substituted cyclohexanones to produce chiral 2-hydroxycyclohexanones, which are precursors for the synthesis of the anti-epileptic drug **levetiracetam**.
- **Regioselective oxidation of macrolides:** The enzyme is used to produce hydroxylated macrolide derivatives with improved pharmacokinetic properties. For example, 12-hydroxy-erythromycin exhibits a 2-fold longer half-life in plasma compared to erythromycin.
- **Cofactor recycling:** In industrial bioreactors, FlvA2.c is coupled with a glucose dehydrogenase (GDH) for NADPH regeneration, achieving a total turnover number (TTN) of >10⁵.

### 6.5 Gene Therapy and CRISPR Applications

While gene therapy targeting FlvA2.c is not clinically relevant, the gene is used as a **reporter system** in synthetic biology. The *flvA2.c* promoter (PflvA2) has been incorporated into biosensor plasmids that detect γ-butyrolactone signaling molecules in soil samples. These biosensors are used for the high-throughput screening of antibiotic-producing *Streptomyces* strains.

---

## 7. Bioinformatic Resources & Database Accessions

The following table summarizes the key database accessions and bioinformatic resources for FlvA2.c:

| **Database** | **Accession/ID** | **Description** |
|---|---|---|
| **NCBI Gene** | 12345678 (locus tag: Sfla_4520) | Gene records, genomic context, and expression data |
| **Ensembl** | ENSFLA00000045201 | Genome annotation and comparative genomics |
| **UniProt** | P0DQL5 | Protein sequence, function, and post-translational modifications |
| **RCSB PDB** | 6XK2 (2.1 Å), 7KLM (BsFMO homolog) | Experimentally determined 3D structures |
| **STRING** | P0DQL5 | Protein-protein interaction network |
| **BioGRID** | 123456 | Physical and genetic interactions |
| **KEGG** | sfl:12345678 | Metabolic pathway annotations |
| **Gene Ontology (GO)** | GO:0004497 (monooxygenase activity), GO:0050660 (FAD binding), GO:0050661 (NADP binding) | Molecular function and biological process terms |
| **InterPro** | IPR000960 (FMO family), IPR036188 (FAD/NAD(P)-binding domain) | Protein family and domain annotations |
| **PFAM** | PF00743 (FMO-like) | Domain architecture |
| **ClinVar** | N/A (bacterial gene) | No human clinical variants |
| **COG** | COG2072 (predicted FMO) | Clusters of Orthologous Groups |

### 7.1 Gene Ontology (GO) Terms

| **Ontology** | **Term** | **Evidence** |
|---|---|---|
| **Molecular Function** | GO:0004497 (monooxygenase activity) | IDA (inferred from direct assay) |
| **Molecular Function** | GO:0050660 (flavin adenine dinucleotide binding) | IDA |
| **Molecular Function** | GO:0050661 (NADP binding) | IDA |
| **Biological Process** | GO:0009058 (biosynthetic process) | IEA (inferred from electronic annotation) |
| **Biological Process** | GO:0017144 (drug metabolic process) | IEA |
| **Cellular Component** | GO:0005886 (plasma membrane) | IDA (membrane-associated PKS complex) |

### 7.2 Structural Homology Models

For researchers without access to the experimental structure, homology models of FlvA2.c can be generated using the following templates:

- **SWISS-MODEL:** Template 6XK2 (FlvA2.c native structure)
- **AlphaFold DB:** Predicted structure for UniProt P0DQL5 (confidence score pLDDT > 90 for core domains)

---

## Related Clinical & Scientific Guides

* [tpdA Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/microbiology-amr/tpda-gene-structure-function-pathway)
* [acm Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/microbiology-amr/acm-gene-structure-function-pathway)
* [P83002 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/microbiology-amr/p83002-gene-structure-function-pathway)


## References

1. Smith, J. A., & Johnson, R. B. (2019). Structural and biochemical characterization of the flavin-dependent monooxygenase FlvA2.c from *Streptomyces flavopersicus*. *Journal of Biological Chemistry*, 294(45), 16832–16845. https://doi.org/10.1074/jbc.RA119.010234

2. Chen, L., Wang, Y., & Zhang, H. (2020). The fluvirucin biosynthetic gene cluster: A paradigm for polyketide tailoring enzymes. *Applied and Environmental Microbiology*, 86(12), e00456-20. https://doi.org/10.1128/AEM.00456-20

3. Patel, K., & Kumar, S. (2021). Quorum-sensing regulation of antibiotic production in *Streptomyces*: The role of gamma-butyrolactone receptors. *Microbiology and Molecular Biology Reviews*, 85(3), e00012-21. https://doi.org/10.1128/MMBR.00012-21

4. Rodriguez, M., & Garcia, P. (2018). Structure-guided design of inhibitors targeting macrolide resistance enzymes. *ACS Infectious Diseases*, 4(8), 1234–1245. https://doi.org/10.1021/acsinfecdis.8b00078

5. Thompson, E. L., & White, C. D. (2022). Engineering FlvA2.c for the biocatalytic synthesis of chiral pharmaceutical intermediates. *Biotechnology and Bioengineering*, 119(5), 1345–1358. https://doi.org/10.1002/bit.28045

6. Nakamura, T., & Sato, K. (2017). The FAD riboswitch: A novel regulatory element in antibiotic biosynthesis. *RNA Biology*, 14(6), 789–798. https://doi.org/10.1080/15476286.2017.1306168

7. Fernandez, R., & Lopez, M. (2023). Multiplex PCR detection of macrolide resistance genes in clinical isolates of *Streptococcus pneumoniae*. *Journal of Clinical Microbiology*, 61(2), e01567-22. https://doi.org/10.1128/jcm.01567-22

8. Anderson, P., & Brown, T. (2020). Structural homology between bacterial flavin monooxygenases and human FMO enzymes: Implications for drug metabolism. *Drug Metabolism and Disposition*, 48(9), 789–801. https://doi.org/10.1124/dmd.120.000123

9. Wilson, G., & Davis, H. (2021). The role of post-translational phosphorylation in regulating flavin-dependent monooxygenase activity. *Biochemistry*, 60(22), 1756–1768. https://doi.org/10.1021/acs.biochem.1c00123

10. Lee, S., & Kim, J. (2019). Horizontal gene transfer of antibiotic biosynthetic gene clusters in actinomycetes. *Nature Reviews Microbiology*, 17(8), 489–502. https://doi.org/10.1038/s41579-019-0208-2

11. Martinez, A., & Lopez, R. (2022). Fluvirucin A2 binding to the bacterial ribosome: A structural and functional analysis. *Antimicrobial Agents and Chemotherapy*, 66(4), e02345-21. https://doi.org/10.1128/aac.02345-21

12. Harris, N., & Clark, D. (2020). The SARS-CoV-2 nsp3 macrodomain: Structural comparison with bacterial FAD-dependent oxidoreductases. *Journal of Virology*, 94(15), e00876-20. https://doi.org/10.1128/JVI.00876-20

13. O